分析Study Results Show Targeted Methylation-Based Solution Has Strong Analytical Sensitivity，Specificity，Precision and Reriability in Many Solid Tumors
GRAIL’s Methylation Platform Research Adds to Data Supporting Potential of GRAIL’s Methylation PlatformAcross the Cancer Care Continuum
ENLO PARK，Calif.--（BUSINESS WIRE）--GRAIL，LLC，ahealthcare company whose mission is to detect cancer early when it can be cured，today presented analytical validata on its recently launched methylation-based post-diagnosis solution to accelerate cancer research（abstract LB297）。Results of the analytical study demonstrated strong analytical sensitivity，specificity and precision of the tissue-free multi-cancer post-diagnosis research solution，which leverages GRail’s proprietary methylation platform to evaluate cell-free DNA（cfDNA）isolated frblood。The findings were presented in a late-breaking poster session at the American Association for Cancer Research（AACR）Annual Meeting 2023in Orlando，held April14-19。
“These results are an important step in establishing the performance of our post-diagnostic methylation-based solution for cancer research，”said Jeffrey Venstrom，MD，Chief Medical Officer at GRail。“Current post-diagnostic cancer detection tests often require tumor tissue and are limited by cifor”。With GRAIL’s methylation technology，the analytical study results showed that we can detect multiple types of cancer with strong sensitivity without the need for a tissue sample.This solution is a versatile option for arange of research uses including cancer prognosis，identification of minimal residual residual didure and nitoration， and biomarker discovery.”
The analytical study analyzed cfDNA blood samples from cancer and non-cancer donors.Analytical sensitivity was assessed in 12different solid tumor types.Results demonstrated arobust median limit of detection（LOD95）of 0.023%based on measures of the abnormally methylated ctDNA fraction。Analytical specificity was98.47%and overall precision across replicates was94.6%。
GRAILannouncedthe availability of its state-of-the-art research use only（RUO）targeted methylation-based solution offering for biopharmaceutical companies in January2023。Several biopharmaceutical partners leveraged early access to the RUO technology solution。
About GRAIL
GRAIL is ahealthcare company whose mission is to detect cancer early，when it can be cured.GRail is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early.The company is using the power of next-nergenculation，incleporation，udies，and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology，and to develop its multi-cancer early detection blood test.GRail is headquartered in Menlo Park，CA with locations in Washington，D.C.，North Carolina，and the United Kingdom.Gialis，llumina，Inc.（NASDAQ:ILMN）currently held separate from Illumina Inc.under the terms of the Interim Measures Order of the European Commission。
强制变形，养护grail.com。
实验室/测试信息
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988（CLIA）and accredited by the College of American Pathologists。GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing.The RUO test was developed，and its performance characteristics were determined by GRAIL.The RUO test is for research use only， not for diagnostic purposes.GRAIL’s current product offerings have not been cleared or approved by the U.S.Food and Drug Administration。
查看source version on businesswire.com：https://www.businesswire.com/news/home/20230419005944/en/
